West Pharmaceutical Services has broken ground on its new pharmaceutical component manufacturing facility in Waterford, Ireland, to meet increasing customer demand.
Expected to become operational in late 2018, the facility will employ close to 150 people in engineering, production and other roles.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The 95,000ft² facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs.
It will also be capable of manufacturing additional proprietary injectable component product lines such as Westar RU and NovaPure for packaging injectable medicines.
West Pharmaceutical Services CEO Eric Green said: "West’s presence in Ireland is of great importance to us for meeting customer demand for high-quality packaging components.
"Packaging systems play an important role in ensuring the purity, long-term stability and efficacy of injectable drug products. The advanced components that will be produced at our state-of-the-art Waterford plant will help our pharmaceutical and biotechnology customers deliver their products to patients."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new facility will also function as a center of excellence for West’s proprietary elastomeric sheeting, which is used to package insulin for use in pen injectors.
West recently completed a multimillion Euro expansion at its manufacturing and development centre in Dublin.
West’s global contract manufacturing solutions provider Tech Group Europe operates from the Dublin centre, offering device design, development and manufacturing services for pharmaceutical, biotechnology and medical device manufacturers.
